Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

12 Aug 2013 07:00

RNS Number : 4202L
ReNeuron Group plc
12 August 2013
 

 

DTR3

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS/ PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

ReNeuron Group plc

2.

State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.2R; or (ii) a disclosure made in accordance with LR 9.8.6R(1); or (iii) in accordance with section 793 of the Companies Act 2006

 

(i)

 

3.

Name of person discharging managerial responsibilities/director

 

Dr. Paul Harper

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3

and identify the connected person

 

Director named in 3.

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 1

 

Interest of person named in 3

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

Ordinary Shares

 

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

Person named in 3

 

8.

State the nature of the transaction

 

Placing of Ordinary Shares

9.

Number of shares, debentures or financial instruments relating to shares acquired

 

Acquisition of 200,000 Ordinary Shares

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

 

0.011%

 

11.

Number of shares, debentures or financial instruments relating to shares disposed

 

 

 

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

 

 

13.

Price per share or value of transaction

 

2.5 pence per Ordinary Share

 

14.

Date and place of transaction

 

9 August 2013

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

Dr. Paul Harper is interested in a total of 451,709 Ordinary Shares in the Company representing approximately 0.025% of issued Ordinary Shares.

 

16.

Date issuer informed of transaction

 

9 August 2013

 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

 

17.

Date of grant

 

 

18.

Period during which or date on which it can be exercised

 

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

 

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

 

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

 

See table of options held by Dr. Paul Harper below:

 

 

 

Number of options

Exercise Price

End of Exercise Period

98,781

12.65p

August 2015

98,688

5.07p

August 2016

258,098

12.2p

August 2017

226,682

4.85p

August 2019

277,797

4.43p

August 2020

417,274

4.31p

August 2021

500,000

3.3pp

August 2022

1,877,300

24.

Name of contact and telephone number for queries

 

Pat Huggins, Reneuron Group Plc

+44 (0)1483 302560

 

 

Name of authorised official of issuer responsible for making notification:

 

Patrick Huggins, Head of Finance and Company Secretary

 

Date of notification: 9 August 2013

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFEETIIAIIV
Date   Source Headline
2nd Mar 20207:00 amRNSBlock Listing Review and Total Voting Rights
24th Feb 20207:00 amRNSPositive long-term data in retinal clinical trial
17th Feb 20207:00 amRNSPositive Phase 2a stroke clinical data published
12th Feb 20207:02 amRNSNotification of Major Holdings
12th Feb 20207:01 amRNSNotification of Major Holdings
12th Feb 20207:00 amRNSNotification of Major Holdings
7th Feb 20201:15 pmRNSNotification of Major Holdings
6th Feb 20209:51 amRNSNotification of Major Holdings
2nd Jan 20207:00 amRNSTotal Voting Rights
18th Dec 201912:10 pmRNSNotification of Major Holdings
16th Dec 20193:00 pmRNSNOTIFICATION OF MAJOR HOLDINGS
6th Dec 20197:00 amRNSInterim Results
18th Nov 20197:00 amRNSNotification of Interim Results
23rd Oct 20197:00 amRNSReNeuron's lead cell line shows further potential
17th Oct 20195:36 pmRNSNotification of Major Holdings
17th Oct 20193:21 pmRNSNotification of Major Holdings
14th Oct 20197:00 amRNSPositive clinical data presented at AAO meeting
2nd Oct 20194:40 pmRNSSecond Price Monitoring Extn
2nd Oct 20194:35 pmRNSPrice Monitoring Extension
2nd Oct 20197:00 amRNSClinical Update and Conference Presentations
12th Sep 201911:21 amRNSResult of AGM
10th Sep 20197:00 amRNSAGM Trading Update
2nd Sep 20197:00 amRNSBlock Listing Review and TVR
21st Aug 20197:00 amRNSAppointments to Scientific Advisory Board
14th Aug 20197:00 amRNSGrant-funded collaboration with exosome platform
2nd Aug 20194:00 pmRNSPosting of Annual Report and Notice of AGM
2nd Aug 20191:12 pmRNSNotification of Major Holdings
1st Aug 201911:50 amRNSTotal Voting Rights
17th Jul 20197:00 amRNSDirector/PDMR Interest in Shares & Share Options
16th Jul 20197:00 amRNSKey patent grants expand exosome IP portfolio
12th Jul 20197:00 amRNSSenior business development appointment
11th Jul 20197:00 amRNSPreliminary Results
8th Jul 20194:30 pmRNSNotification of Major Holdings
1st Jul 201911:00 amRNSPrice Monitoring Extension
1st Jul 20197:00 amRNSTotal Voting Rights
18th Jun 20194:01 pmRNSNotification of Major Holdings
18th Jun 20197:00 amRNSWebcast of Preliminary Results
14th Jun 201911:09 amRNSReNeuron wins Breakthrough of the Year Award
3rd Jun 20197:00 amRNSTotal Voting Rights
31st May 20197:00 amRNSJefferies 2019 Global Healthcare Conference
9th May 20195:05 pmRNSExercise of options, PDMR dealing and TVR
8th May 20197:00 amRNSYear-end update and results notification
2nd May 20193:43 pmRNSTotal Voting Rights
26th Apr 20194:40 pmRNSSecond Price Monitoring Extn
26th Apr 20194:35 pmRNSPrice Monitoring Extension
26th Apr 20197:00 amRNSClinical update and conference presentation
18th Apr 20193:40 pmRNSShare Purchases by Directors
12th Apr 20192:36 pmRNSExercise of Share Options and TVR
11th Apr 20194:31 pmRNSShare Purchases by Directors
10th Apr 20192:37 pmRNSDirector/PDMR Shares and Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.